Day: September 20, 2021

REWE Group, one of Germany’s leading food retailers, has signed a 10-year power purchase agreement with Ørsted to procure 100 MW of green electricity from Ørsted’s Borkum Riffgrund 3 offshore wind farm which is set to become operational in 2025. Having procured electricity from renewable energy sources since 2008, the agreement with Ørsted represents REWE Group’s largest renewable energy offtake agreement to date and makes REWE Group the first German food retailer to purchase electricity from an offshore wind farm in the North Sea. The 100 MW of green power from Borkum Riffgrund 3 equals the power consumption of 1,500 REWE stores. REWE Group has a goal of becoming climate neutral by 2040. “Our goal is to become climate neutral by 2040,” said Lionel Souque, CEO of REWE Group. “It is obviously an ambitious goal. But it is also a goal that...

Press contact: Sam ConnattyTel.: +44 (0) 370 904 3601Email: sam.connatty@capgemini.com Capgemini and McDonald’s extend strategic provider agreement to develop, deploy and maintain McDonald’s digital and restaurant technology PARIS and CHICAGO, September 20, 2021 – Capgemini today announced that it has signed a multi-year extension to its IT strategic provider agreement with McDonald’s Corporation. Through this agreement, Capgemini will continue to develop, deploy, and maintain certain digital, e-commerce, and restaurant technology solutions that power consumer engagement across channels such as kiosk, Point of Sale (POS), web, global mobile application, drive thru and home delivery. “McDonald’s has successfully undergone a rapid modernization of its platforms, digital channels and restaurant technology in the past four years in support...

The Nomination Committee for Copperstone Resources AB (publ) has informed the company that it is proposing changes to the company’s board composition, and that an Extraordinary General Meeting will be held on October 14, 2021. Markus Petäjäniemi is proposed by the Nomination Committee to be elected as a new Board member and deputy Chairman of the Board. “We are extremely positive that Markus Petäjäniemi has been proposed by the Nomination Committee and has accepted a seat on the board as deputy Chairman. He has been a member of LKAB’s Group Management for over 10 years and has served on the boards of several leading subsidiaries within LKAB. We thus gain access to additional heavy industry experience on the board with an emphasis on logistics, innovation and sustainability”, says Jörgen Olsson, Chairman of the Board. The...

OSE Immunotherapeutics reminds the presentation on positive data of Tedopi® in non-small cell lung cancer today at 13:30 CEST NANTES, France, Sept. 20, 2021 (GLOBE NEWSWIRE) — OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) announces the presentation of Phase 3 clinical results of Tedopi® today at 13:30 CEST in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Virtual Congress. Following the publication of the abstract on the ESMO website, Pr. Benjamin Besse, Director of Clinical Research at Gustave Roussy (Villejuif, France) and Principal Investigator, will feature the positive results of the Phase 3 clinical trial with Tedopi® (Atalante 1) in non-small cell lung cancer patients after failure to immune checkpoint inhibitor (PD-1/PD-L1) in a late-breaking oral presentation. The abstract...

Following surufatinib launch in China in January 2021; NDA acceptance by the U.S. FDA for review in June 2021; and MAA validation by the EMA in July 2021 all for advanced neuroendocrine tumors HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 19, 2021 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that it has initiated a Japan registration-enabling bridging study for surufatinib to support the registration of surufatinib in the treatment of patients with advanced neuroendocrine tumors (“NETs”). The first patient was dosed on September 15, 2021. Based on dialogue with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), it was agreed that the surufatinib Japanese new drug application (“NDA”) for the treatment of advanced NETs include results from a pivotal...